Compare HOFT & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOFT | VTVT |
|---|---|---|
| Founded | 1924 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.6M | 148.7M |
| IPO Year | 1999 | 2015 |
| Metric | HOFT | VTVT |
|---|---|---|
| Price | $12.34 | $31.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $53.00 |
| AVG Volume (30 Days) | 35.8K | ★ 51.6K |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $278,139,000.00 | N/A |
| Revenue This Year | $17.37 | N/A |
| Revenue Next Year | $9.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.46 | $14.00 |
| 52 Week High | $15.99 | $44.00 |
| Indicator | HOFT | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 39.53 |
| Support Level | $12.15 | $30.62 |
| Resistance Level | $13.47 | $33.11 |
| Average True Range (ATR) | 0.88 | 2.70 |
| MACD | -0.16 | -0.84 |
| Stochastic Oscillator | 13.65 | 21.67 |
Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.